JOHN HARDY: Open Payments
NPI 1619032182 · PUEBLO, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$169,949 in 269 payments from 13 companies in 2025. Trend: 2023 $139,310 · 2024 $133,865 · 2025 $169,949
Speaker / faculty: $129,027Travel & lodging: $19,243Consulting: $15,275Food & beverage: $6,404
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 132 | $101,532 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 46 | $35,345 |
| E.R. Squibb & Sons, L.L.C. | 49 | $28,525 |
| ABBVIE INC. | 5 | $2,500 |
| Janssen Scientific Affairs, LLC | 7 | $812 |
| Alkermes, Inc. | 11 | $610 |
| Vanda Pharmaceuticals Inc. | 4 | $176 |
| Teva Pharmaceuticals USA, Inc. | 5 | $170 |
| Lundbeck LLC | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $54 |
Products named: INGREZZA, CAPLYTA, COBENFY, VRAYLAR, SPRAVATO, ARISTADA, LYBALVI, FANAPT.
Industry payments across CO — which companies pay providers there.
